TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10991865

Group type: EXPERIMENTAL
Intervention: 100 mg of racemic dOTC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 200 mg of racemic dOTC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 400 mg of racemic dOTC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 800 mg of racemic dOTC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1600 mg of racemic dOTC
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8854777

Group type: EXPERIMENTAL
Intervention: Continuous hepatic artery infusion of 5-FU (500 mg x 4 days/week for six weeks from 2 weeks after surgery)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral 5-FU from 2 weeks after surgery
Number of subjects: 18
Study: 1296454

Group type: EXPERIMENTAL
Intervention: IL-2 at a dose of 3 million IU subcutaneously twice/daily for 6 days/week for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 once/daily in the evening
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 once/daily plus MLT at 10 or at 50 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 given twice/daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 plus MLT
Number of subjects: 30

Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 30
Study: 6084924

Group type: EXPERIMENTAL
Intervention: Desogestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Levonorgestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Number of subjects: 54
Study: 30022567

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) for 8 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Psychopharmacological consultation
Number of subjects: 39
Study: 26655493

Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (1 μg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (10 μg/kg)
Number of subjects: 21
Study: 24371300

Group type: EXPERIMENTAL
Intervention: Oral antioxidant therapy (mixed tocopherols 666 IU/d plus α-lipoic acid 600 mg/d)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 353
Study: 22770692

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA) as a supplement to general anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional general anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 60
Study: 20602877

Group type: EXPERIMENTAL
Intervention: Video-audio eyewear (SI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Video-audio eyewear (FI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal method (SC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal method (FC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Video-audio eyewear
Number of subjects: 40
Study: 18528400

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15948810

Group type: EXPERIMENTAL
Intervention: Endoscopic banding ligation
Number of subjects: 52

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 52
Study: 12792707

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally every 8 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin (300 mg on the first day, 100 mg/day thereafter)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Captopril-Aspirin (Captopril on the first day, followed by Aspirin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspirin-Captopril (Aspirin on the first day, followed by Captopril)
Number of subjects: 40
Study: 12147937

Group type: EXPERIMENTAL
Intervention: Losartan-based therapy
Number of subjects: 9193

Group type: COMPARATOR
Intervention: Atenolol-based therapy
Number of subjects: 9193
Study: 10189602

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nortriptyline (25-100 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 76
Study: 7851166

Group type: EXPERIMENTAL
Intervention: High anastomosis (top of anal columns)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low anastomosis (dentate line)
Number of subjects: 47
Study: 1694647

Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate (20 mg elemental zinc twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 40
Study: 6990674

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 55
Study: 31174846

Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scopolamine (both dosages)
Number of subjects: 60
Study: 28402865

Group type: EXPERIMENTAL
Intervention: Facilitation of contralesional dorsal premotor cortex (cPMd) using repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard approach involving inhibition of contralesional motor cortex (cM1)
Number of subjects: 15
Study: 25661136

Group type: EXPERIMENTAL
Intervention: IV midazolam
Number of subjects: 156

Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 156
Study: 23515902

Group type: EXPERIMENTAL
Intervention: In-person active intervention
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Greater weight loss
Number of subjects: 451
Study: 21332580

Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 91
Study: 19586656

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 9319
Study: 17846073

Group type: EXPERIMENTAL
Intervention: Voluntary trunk rotation (TR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Voluntary trunk rotation and half‐field eye‐patching (TR + EP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional training (Control)
Number of subjects: 60
Study: 15279521

Group type: EXPERIMENTAL
Intervention: Reduction counseling plus nicotine replacement therapy (NRT) plus brief advice to quit
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Motivational advice plus brief advice
Number of subjects: 616

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 616
Study: 11595291

Group type: EXPERIMENTAL
Intervention: Cytokines administration with or without therapeutic vaccination in HAART treated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment interruption (TI) or drug therapy change from a PI- to a non-nucleoside-based HAART regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAART (Protease inhibitor-based)
Number of subjects: 0
Study: 9625829

Group type: EXPERIMENTAL
Intervention: Surgical treatment (lobectomy, sleeve lobectomy, bilobectomy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-grade malignant tumors group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Preoperative examination
Number of subjects: 10
Study: 7848400

Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 38
Study: 3278876

Group type: EXPERIMENTAL
Intervention: 150 micrograms levothyroxine (T4) daily (group I, n = 35)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine and 130.8 micrograms potassium iodide daily (group II, n = 39)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 100 micrograms iodide daily (prophylactic administration after initial treatment)
Number of subjects: 74
Study: 29385323

Group type: COMPARATOR
Intervention: LY3016859 (LY) administered intravenously (0.1-750 mg) or subcutaneously (50 mg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: LY3016859 (LY) administered intravenously (10-750 mg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: LY3016859 (LY) administered intravenously (50-750 mg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: LY3016859 (LY)
Number of subjects: 116
Study: 27721247

Group type: EXPERIMENTAL
Intervention: Oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oxycodone group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dezocine group
Number of subjects: 51
Study: 24566612

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Comparison between Manual Acupuncture and Electroacupuncture)
Number of subjects: 60
Study: 22070421

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Lifetime history of mood disorders
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Lifetime history of anxiety disorders
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Lifetime history of substance use disorder
Number of subjects: 223
Study: 20398484

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal Control
Number of subjects: 64
Study: 18547955

Group type: EXPERIMENTAL
Intervention: 20 IU/m2 body surface area/week of r-hGH
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 40 IU/m2 body surface area/week of r-hGH
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both doses of r-hGH
Number of subjects: 29
Study: 15794968

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 17137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17137
Study: 15128360

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: High-Fiber Diet (HFD)
Number of subjects: 98
Study: 11093724

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 8881824

Group type: EXPERIMENTAL
Intervention: Double blind positive food challenge (DBPCFC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Double blind negative food challenge (DBPCFC)
Number of subjects: 15
Study: 1403464

Group type: EXPERIMENTAL
Intervention: GI priming plus TPN
Number of subjects: 40

Group type: COMPARATOR
Intervention: TPN alone
Number of subjects: 40
Study: 3892406

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 3296967

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31477545

Group type: EXPERIMENTAL
Intervention: Fixed-combination, low-dose, triple-pill antihypertensive therapy (amlodipine, telmisartan, chlorthalidone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25466805

Group type: EXPERIMENTAL
Intervention: Nebulized amphotericin B (2.5 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (0.5 mg)
Number of subjects: 40
Study: 23419053

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by community pharmacists, consisting of a brief motivational discussion lasting approximately 10 minutes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention control condition, where participants receive an alcohol information leaflet with no opportunity for discussion.
Number of subjects: 0
Study: 21464720

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: No PPI
Number of subjects: 34
Study: 18769636

Group type: EXPERIMENTAL
Intervention: Various pharmacological treatment modalities for TBI
Number of subjects: 1500000

Group type: EXPERIMENTAL
Intervention: Basic and clinical research findings
Number of subjects: 1500000

Group type: EXPERIMENTAL
Intervention: Prospective clinical trials
Number of subjects: 1500000
Study: 16790647

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study: 12394678

Group type: EXPERIMENTAL
Intervention: Individualized mentored instruction
Number of subjects: 20

Group type: COMPARATOR
Intervention: No additional training
Number of subjects: 20
Study: 10709673

Group type: EXPERIMENTAL
Intervention: Exisulind (Sulindac sulfone) 200 mg, 300 mg, or 400 mg twice daily for six months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exisulind (Sulindac sulfone) at all dose levels
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exisulind (Sulindac sulfone)
Number of subjects: 18
Study: 7596054

Group type: EXPERIMENTAL
Intervention: Arm IV: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐fluorouracil (5‐FU) 200 mg/body/day p.o. for six months
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Arm V: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Arm VI: surgery alone (control)
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Arm I: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐FU 200 mg/body/day p.o. for six months
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Arm II: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Arm III: surgery alone (control)
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Dukes C patients in Arm II: postoperative treatment
Number of subjects: 1805

Group type: EXPERIMENTAL
Intervention: Arm I: Dukes C patients
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Arm III: surgery alone (control) for Dukes C patients
Number of subjects: 1805
Study: 2185045

Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of ascitic fluid guided by ultrasound
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 474432

Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 26
Study: 31794974

Group type: EXPERIMENTAL
Intervention: 4-weeks active intermittent theta burst stimulation (iTBS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 2-weeks sham stimulation
Number of subjects: 46
Study: 29949473

Group type: EXPERIMENTAL
Intervention: Heat-stable carbetocin (100 μg)
Number of subjects: 29645

Group type: COMPARATOR
Intervention: Oxytocin (10 IU)
Number of subjects: 29645
Study: 26908570

Group type: EXPERIMENTAL
Intervention: Sensor augmented pump therapy with low glucose insulin suspension
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sensor accuracy
Number of subjects: 38
Study: 24102867

Group type: EXPERIMENTAL
Intervention: Mixture of hydroxyapatite and autogenous bone (80:20 w/w)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 10
Study: 22833010

Group type: EXPERIMENTAL
Intervention: Maximal handgrip contraction (100% MVC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Submaximal handgrip contraction (30% MVC)
Number of subjects: 0
Study: 20724560

Group type: EXPERIMENTAL
Intervention: Heat acclimation (10-day program at ∼50% VO2max in 40°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (8 matched subjects, identical exercise in cool environment)
Number of subjects: 12
Study: 18981499

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (Artequin)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem)
Number of subjects: 470
Study: 16737798

Group type: EXPERIMENTAL
Intervention: Neurocognitive Enhancement Therapy with Work Therapy (NET+WT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Work Therapy only (WT only)
Number of subjects: 152
Study: 12651805

Group type: EXPERIMENTAL
Intervention: CYP450 GeneChip assay
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: AS‐PCR
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: CYP2D6 subgroups (PM, IM, EM, UM)
Number of subjects: 236
Study: 10371095

Group type: EXPERIMENTAL
Intervention: Terfenadine (1 mg/kg per body weight per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9049968

Group type: EXPERIMENTAL
Intervention: VACPE regimen (vincristine 2 mg d1, adriamycin 25 mg/m2 d1-3, cyclophosphamide 800 mg/m2 d1, prednisone 60 mg/m2 d1-7, etoposide 120 mg/m2 d1-3)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: VACPE regimen
Number of subjects: 27
Study: 1910957

Group type: EXPERIMENTAL
Intervention: Intermittent cyclic etidronate (400 mg/day oral for 2 weeks, followed by 13 weeks off treatment)
Number of subjects: 37

Group type: COMPARATOR
Intervention: ADFR treatment (100 micrograms/day oral triiodothyronine for 7 days, followed by 400 mg/day etidronate for 2 weeks and 12 weeks off treatment)
Number of subjects: 37
Study: 7102850

Group type: EXPERIMENTAL
Intervention: In-person interviews
Number of subjects: 546

Group type: COMPARATOR
Intervention: Telephone interviews
Number of subjects: 546
Study: 31481560

Group type: EXPERIMENTAL
Intervention: Basic carbohydrate counting programme
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Advanced carbohydrate counting programme including an automated bolus calculator
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual dietary care
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 231
Study: 30636761

Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 27290676

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES)
Number of subjects: 525
Study: 23730718

Group type: EXPERIMENTAL
Intervention: Autonomy support at 6 months
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Autonomous self-regulation at 6 months
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Encouragement of healthy eating at 6 months
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Other forms of directive support
Number of subjects: 201
Study: 22885681

Group type: EXPERIMENTAL
Intervention: Mussel-mimetic tissue adhesive (mussel glue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 0
Study: 20977850

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg, once a day for 3-8 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) 0.4 ml, twice a day for 3-8 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 105

Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 105
Study: 18762476

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg daily)
Number of subjects: 3350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3350
Study: 15700050

Group type: EXPERIMENTAL
Intervention: Goserelin ('Zoladex') injection using 16-gauge needle
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Leuprorelin ('Prostap') injection using 23-gauge needle
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Goserelin ('Zoladex') injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Leuprorelin ('Prostap') injection
Number of subjects: 50
Study: 12581262

Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg intravenous infusion)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 10479672

Group type: EXPERIMENTAL
Intervention: Fluindione at INR 1.5 to 2.0
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluindione at INR 2.1 to 3.0
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluindione plus aspirin (325 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluindione plus aspirin
Number of subjects: 10
Study: 8792753

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 1624004

Group type: EXPERIMENTAL
Intervention: hCG administration (2,500 U two times weekly between the 4th and 8th week of gestation)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: hCG administration in hMG/hCG generated gestations
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: hCG administration in CC/hCG-induced pregnancies
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: hCG administration in spontaneous conceptions
Number of subjects: 447
Study: 6342220

Group type: EXPERIMENTAL
Intervention: Plasma exchange on six consecutive days at a mean exchange volume of 40.6 ml/kg of body weight each day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard immunosuppression only
Number of subjects: 27
Study: 31457091

Group type: EXPERIMENTAL
Intervention: Gluten peptide injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gluten ingestion
Number of subjects: 0
Study: 29702502

Group type: EXPERIMENTAL
Intervention: Peri‐operative oral caffeine (400 mg every 8 h for 2 days)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 27484013

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 326